U.S. markets closed

  • S&P 500

    4,682.80
    -0.05 (-0.00%)
     

  • Dow 30

    36,087.45
    -12.86 (-0.04%)
     

  • Nasdaq

    15,853.85
    -7.11 (-0.04%)
     

  • Russell 2000

    2,400.93
    -10.84 (-0.45%)
     

  • Crude Oil

    80.80
    -0.08 (-0.10%)
     

  • Gold

    1,864.20
    -2.40 (-0.13%)
     

  • Silver

    25.13
    +0.02 (+0.10%)
     

  • EUR/USD

    1.1377
    +0.0005 (+0.05%)
     

  • 10-Yr Bond

    1.6230
    +0.0410 (+2.59%)
     

  • GBP/USD

    1.3409
    -0.0005 (-0.03%)
     

  • USD/JPY

    114.1440
    +0.0150 (+0.01%)
     

  • BTC-USD

    62,902.98
    -3,105.83 (-4.71%)
     

  • CMC Crypto 200

    1,579.75
    -45.29 (-2.79%)
     

  • FTSE 100

    7,351.86
    +3.95 (+0.05%)
     

  • Nikkei 225

    29,776.80
    0.00 (0.00%)
     
Webinar:

Yahoo Finance Plus presents 'Energy: A Return to Fossil Fuels'

Is the fossil fuel recovery real, or a stepping stone to a fossil-free future? Register now for our 11/17 webinar at 2PM ET

Virtual Roundtable Panel Discussion in honor of Diabetes Awareness Month and World Diabetes Day - Using Digital Tools to Address Ethnic and Socioeconomic Barriers to Drive Improved Clinical Outcomes in Underserved Areas

·3 min read

~Study Results suggest important role of digital health interventions to manage diabetes in people with low numeracy and low literacy in an underserved area

MALVERN, Pa., Nov. 15, 2021 /PRNewswire/ --

LifeScan Diabetes Institute (LDI) is passionate about addressing the worldwide epidemic of diabetes through world-class experiential learning. LDI comes alongside healthcare practitioners on the front lines of diabetes care as a trusted source of education, training, and support so they are better equipped to empower people with diabetes to make better use of tools and insights at their fingertips.
LifeScan Diabetes Institute (LDI) is passionate about addressing the worldwide epidemic of diabetes through world-class experiential learning. LDI comes alongside healthcare practitioners on the front lines of diabetes care as a trusted source of education, training, and support so they are better equipped to empower people with diabetes to make better use of tools and insights at their fingertips.

EVENT INFORMATION

What:

Virtual Roundtable Panel Discussion in honor of Diabetes Awareness Month and World Diabetes Day - Using Digital Tools to Address Ethnic and Socioeconomic Barriers to Drive Improved Outcomes



Why:

Digital health tools and patient-centric interventions can drive engagement and improve clinical outcomes for people with diabetes while advancing health equity in underserved communities. We'll explore some of the socioeconomic barriers to improved diabetes self-management and discuss proven ways we can integrate digital health tools and other patient-centric interventions to drive engagement and improve clinical outcomes.



When:

Tuesday, November 16


5-6 pm PT / 8-9 pm ET



Where:

Live virtual discussion. Registration is required by going here.


Please note that a replay will be available on Dec. 6 by going to LifeScan Diabetes Institute.

Details:
Join the LifeScan Diabetes Institute along with panelists from LifeScan, Association of Diabetes Care and Education Specialists (ADCES) and LCH Health and Community Services (LCH) for a virtual roundtable panel session to learn more about the Tu Salud study, published in Diabetes Spectrum, a peer-reviewed journal of the American Diabetes Association, and to discuss the key learnings that suggest the important role of digital health interventions to manage diabetes in people with low numeracy and low literacy in underserved areas.

Moderated by Amparo Gonzalez, MPH, RN, CDCES, FADCES
Global Head LifeScan Diabetes Institute

Panelists:

  • Elizabeth Holt, MD, FACE
    Head of Global Medical, Clinical and Safety at LifeScan

  • Lorena Drago, MS, RD, CDN, CDCES
    Multicultural Nutrition Education Expert
    ADCES, Diversity, Equity, and Inclusion Chair and In Practice Editorial Board

  • Fatima Sattar, MSN, CRNP, FNP-C, PMHNP-BC
    LCH Services Health Care Provider

  • Johana Guzman, RN
    LCH Services Health Study Coordinator

  • Larry Katz, PhD
    Tu Salud Study Primary Author

Diabetes in Hispanic and Latino American Adults
It's estimated that over their lifetimes, US adults overall have a 40% chance of developing type 2 diabetes. For Hispanic/Latino adults in the US, the chance of developing type 2 diabetes is more than 50%, they are likely to develop it at a younger age and they experience more severe diabetes complications1. The prevalence and incidence of type 2 diabetes, as well as rates of hospital admissions and diabetes-related complications within the Hispanic/Latino population in the US, are higher than the national average likely influenced by a variety of cultural and social factors, including low numeracy and low literacy2,3,4.

1 https://www.cdc.gov/diabetes/library/features/hispanic-diabetes.html

2 Agency for Healthcare Research and Quality. National Healthcare Quality Report, 2013 (AHRQ Publication No. 14-0005). Rockville, MD, U.S. Department of Health and Human Services, 2014

3 Testerman J, Chase D. Influences on diabetes self-management education participation in a low-income, Spanish-speaking,Latino population. Diabetes Spectr 2018;31:47–57

4 Aguayo-Mazzucato C, Diaque P, Hernandez S, Rosas S, Kostic, A, Caballero AE. Understanding the growing epidemic of type 2 diabetes in the Hispanic population living in the United States.Diabetes Metab Res Rev 2019;35:e3097

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/virtual-roundtable-panel-discussion-in-honor-of-diabetes-awareness-month-and-world-diabetes-day---using-digital-tools-to-address-ethnic-and-socioeconomic-barriers-to-drive-improved-clinical-outcomes-in-underserved-areas-301424703.html

SOURCE LifeScan Diabetes Institute

Recommended Stories

  • AstraZeneca, Moderna Shares Early Cut Data For mRNA Candidate In Heart Failure

    Moderna Inc (NASDAQ: MRNA) announced data from the AstraZeneca Plc (NASDAQ: AZN)-led Phase 2 (EPICCURE) study evaluating AZD8601 in patients undergoing coronary artery bypass grafting (CABG). AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A). In the trial, seven were treated with AZD8601, while four were given a placebo. After six months of follow-up, investigators concluded the drug met the primary endpoints on safety and tolerability, while the explo

  • Why 2022 Medicare Part B Premiums Soared

    The surprisingly big jump in Medicare Part B premiums for 2022 reflects the sky-high cost of a controversial Alzheimer’s disease drug. The premium hike will put more than a dent in the newly increased Social Security cost-of-living allowance, which worked out … Continue reading → The post Why 2022 Medicare Part B Premiums Soared appeared first on SmartAsset Blog.

  • PhaseBio shares fall despite positive late-stage study results for lead drug candidate

    PhaseBio Pharmaceuticals reported positive late-stage clinical trial data for its lead new drug candidate Monday. The announcement, however, did not generate excitement on Wall Street as the Malvern company's stock closed down about 18% at $3.02 per share. PhaseBio's experimental drug, bentracimab, is being developed to reverse the anti-clotting effects of ticagrelor, an anti-platelet medicine, in patients who require urgent surgery or an invasive procedure, or are experiencing uncontrolled major or life-threatening bleeding.

  • The #1 Worst Drink for Your Liver, New Study Says

    Maybe you intuitively understand that because the liver filters toxins from your body, it's essential to keep this important organ healthy. And often, when we talk about liver damage, the first thing that comes to mind is alcohol. However, new research reveals an entirely different category of drink is what commonly harms the liver… and unlike alcohol, there's no minimum required age for this type of beverage.Keep reading to learn what medical and public health researchers in Boston say may be t

  • Covid Cases Are Rising Again. Booster Rollout Could Expand as a Result.

    The threat of a winter surge in the Northern Hemisphere is looming, just as the so-called Delta wave begins to recede in the U.S. This time, it could push forward a resolution of the unanswered questions around the U.S. booster rollout. U.S. regulators stopped short of allowing third doses of Covid-19 vaccines for all adults this fall, stymying the rollout that the Biden administration had promised in August. Now, with cases rising again, it appears as though the administration is going to push again for universal boosting for all adults in the U.S.

  • Why Tonix Pharmaceuticals Holding Zoomed Higher Today

    Shares of Tonix Pharmaceuticals (NASDAQ: TNXP), a much-discussed title among the meme stock crowd, had the latest in a series of up-and-down trading days on Monday. The biotech's stock flew nearly 7% higher on the back of encouraging patent news. Tonix announced that last Tuesday, it received a patent for "Trefoil Family Factor Proteins and Uses Thereof."

  • Dr. Fauci Warns This is the Biggest Risk When Traveling Right Now

    People all across the U.S. decided not to travel to see loved ones for Thanksgiving and Christmas last year, while the coronavirus surged far and wide. But as we approach our second holiday season in the COVID pandemic, things are a lot different. Millions of people are now vaccinated, making the idea of traveling and gathering with others a much safer proposition this year than it was in 2020. And several health officials have agreed, including Centers for Disease Control and Prevention (CDC) D

  • Rocket Pharma To Test Lower Dose Of Gene Therapy In Genetic Disorder Trial

    Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced updated data from the Phase 1 trial evaluating a single intravenous infusion of RP-A501, an investigational gene therapy, for Danon Disease. Danon disease is characterized by weakening of the heart muscle, weakening of skeletal muscles, and intellectual disability. The update includes interim safety and efficacy data from patients in the low-dose (6.7e13 vg/kg; n=3) and high-dose (1.1e14 vg/kg; n=2) adult and adolescent cohorts. Data demons

  • If You're Over 65, Never Do This In the Bathroom, Mayo Clinic Warns

    A lot can change with age, and for some seniors, those changes may include their bathroom habits. A 2014 report published by the Centers for Disease Control and Prevention (CDC) reveals that 51 percent of adults over the age of 65 suffer from bladder or bowel incontinence—a pair of conditions that often cause a frequent, sudden, or uncontrollable urge to go. "We found that half the population experienced urinary leakage or accidental bowel leakage, and about 25 percent had moderate, severe or ve

  • Rigel to lay off 31, focus on later-stage drugs, including Covid program

    The company is exiting early research and looking for "other opportunities" that complement its work in cancer.

  • Moderna's COVID-19 vaccine boosters OK's by Health Canada

    Moderna Inc. said Friday that a booster dose for its COVID-19 vaccine has been authorized by Health Canada for use in people at least 18 years old, at least six months after the completion of the primary two-dose regimen. Last month, U.S. regulators had signed off on extending boosters to Americans who got the Moderna or Johnson & Johnson vaccine, and said eligible people can get a brand different from the shots they originally received. Moderna's stock fell 1.1% in morning trading. Earlier, the

  • OPNT: Raises 2021 Full-Year Revenue and Cash Guidance...

    By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Financial Update On November 11, 2021, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced financial results for the third quarter of 2021. The company reported $16.3 million in revenue for the third quarter of 2021, compared to $9.1 million in revenue for the third quarter of 2020. The revenue in the third quarter of 2021

  • Ways You're Catching Covid Without Knowing It

    Nearly two years into the pandemic, you might think you know all the best practices necessary to avoid contracting COVID. But the Delta variant, vaccines, booster shots and the resumption of normal life have changed—and continue to change—the safety equation. Add a bit of COVID fatigue most of us are suffering from, and it's entirely possible you might catch COVID this winter without knowing it. Here's what science and experts say are the most common ways that could happen. Read on to find out m

  • You're Almost Definitely Not Getting Enough Sleep

    Your heart, your brain, and your mood are just three things that function much better when you get enough sleep. Here's how much sleep you need every night.

  • Hospital revokes Houston doctor's privileges for 'spreading dangerous misinformation' about covid on Twitter

    Mary Bowden, an ear, nose and throat doctor at Houston Methodist Hospital, says vaccine mandates are wrong. It's a sentiment she has tweeted about numerous times this month, even declaring last week that she is "shifting my practice" to focus on treating unvaccinated patients.Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. Bowden has also used her personal Twitter account to promote the anti-parasitic drug ivermectin as a treatment f

  • EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment

    NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. The company believes the formulation may have advantages in terms of drug bioavailability over oral pills, because of partial sublingual absorption that avoids the gastrointestinal tract. What To Know: NanoViricides says this oral gummies formulation would be attractive to patients, especially children, over oral pills. The c

  • Philips shares tumble as FDA raises concern about silicone foam

    Koninklijke Philips was on track for its worst single session in 19 years, falling 9.6%, after the Food and Drug Administration's inspection of a U.S. facility, following a recall of breathing assistance machines. The FDA said it obtained information during an inspection about the silicone-based foam used in a similar device marketed outside the U.S.,

  • Explainer-Delta dominates the world, but scientists watch for worrisome offspring

    The Delta variant of the SARS-CoV-2 virus now accounts for nearly all of the coronavirus infections globally, fueled by unchecked spread of the novel coronavirus in many parts of the world. The Delta variant, first detected in India in December 2020, remains the most worrisome version of the SARS-CoV-2 virus. The World Health Organization classifies Delta as a variant of concern, a category that means the variant is capable of increasing transmissibility, causing more severe disease or reducing the benefit of vaccines and treatments.

  • Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 41,358,603 million units, or 248,516 pounds, of used contact lens, eye and lens care materials. The programs are made possible through a collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste.

  • Over 70? Having This Many Alcoholic Drinks a Week Lowers Your Death Risk

    As you age, staying on top of your health usually involves staying active, maintaining a healthy diet, and dropping any bad habits such as smoking. But when it comes to the topic of having the occasional glass of wine or cocktail, studies have gone back and forth on whether a tiny tipple now and then could be beneficial or harmful in any way. Now, a new study has added evidence to the pile that seniors aged 70 and older could lower their death risk by having a small number of alcoholic drinks ea